martedì, 5 maggio 2026

Notizie Newsletter

Call for all sponsors to publish clinical trial results in EU database

July 3, 2019 - The European Commission (EC), the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have co-signed a letter reminding all sponsors of clinical trials conducted in the European Union of their obligation to make summaries of results of ...
Leggi tutto

Medicine shortages: EU network takes steps to improve reporting and communication

July 4, 2019 - The European Union task force set up to address problems with medicines supply has published two documents today: guidance for marketing authorisation holders on reporting of shortages in the EU; good practice guidance for communication to the public on medicines’ ...
Leggi tutto

Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial. National Lung Screening Trial Writing Team 1

The National Lung Screening Trial (NLST) randomized high-risk current and former smokers to 3 annual screens with either low-dose computed tomography (LDCT) or chest radiographs (CXR) and demonstrated a significant reduction in lung cancer mortality in the LDCT arm after ...
Leggi tutto

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

The aim of the current study was to report the efficacy of topical and systemic treatments for immune-related cutaneous adverse events (ircAEs) attributed to checkpoint inhibitors in an uncontrolled cohort of patients referred to oncodermatology clinics. A retrospective ...
Leggi tutto

4 luglio 2019 – Impegnati a risolvere questione carenze ma rassicuriamo i pazienti

EMA confirms WeWork as new sub-tenant for 30 Churchill Place; EMA also settles court case with Canary Wharf Group

July 4, 2019 - The European Medicines Agency has reached an agreement with Canary Wharf Ltd over its premises at 30 Churchill Place, London, in accordance with the discussions held with the EU budgetary authorities. EMA announces today that it has sublet all of its 284,704 ...
Leggi tutto

1 luglio 2019 – Comunicazione EMA su medicinali a base di Lisati Batterici

FDA approves new treatment for refractory multiple myeloma

July 3, 2019 - Today, the U.S. Food and Drug Administration granted accelerated approval to selinexor tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least ...
Leggi tutto

IMWG Consensus Recommendations on Imaging in Monoclonal Plasma Disorders

June 28, 2019 - Just as newer drugs have significantly improved outcomes for patients with multiple myeloma in the past decade, newer imaging techniques are upgrading detection of the disease, leading to earlier treatment, but standards to help guide clinicians on the optimal ...
Leggi tutto

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

Treatment options are limited for patients with recurrent/metastatic low-grade ovarian cancers (LGOCs) and serous borderline ovarian tumors (SBOTs) as response rates to chemotherapy are low. A subset of patients appears to derive clinical benefit from antiestrogens, but ...
Leggi tutto